Daily peptides like Ipamorelin are harder to manage properly on trips
Pognan F, Beilmann M, Boonen HCM, Czich A, Dear G, Hewitt P
160,161 For example, HM15211, a triple agonist developed by Hanmi Pharmaceutical in South Korea that activates GLP-1R, GIPR and GCGR has entered early clinical trials for the treatment of obesity and non-alcoholic steatohepatitis (NASH)
This distinction matters for researchers because it means the BPC-157 peptides activity range was discovered through observation rather than design
For a structured comparative research perspective examining the mechanistic differences between these compounds, see: Semax vs Selank vs Dihexa Key Research Differences